Navigation Links
Long-Term Extension of Ulcerative Colitis Study Shows Remicade,Responders Maintained Improvement Through Two Years of Follow-Up

on long term is a significant benefit to patients."

Separate data also presented at DDW today show the significant impact of UC on patients' productivity, employment and social activities. A survey of 1,000 patients who rated their UC symptoms on a scale of 1 to 5, with 5 being very severe, showed that patients with more severe disease reported greater disability, significantly more days missed from work and significantly more days of reduced productivity, compared with patients with less severe disease (P < 0.01). In fact, 19 percent of patients with the most severe disease were on long- or short-term medical leave from work, compared with less than seven percent of patients whose disease was less severe (P < 0.01). Of patients who were employed, those with the most severe disease missed an average of 19 days of work in the past year, compared with one day for those with the mildest disease (P < 0.01). Furthermore, even when at work, patients who rated their disease as more severe reported being less productive on more than 30 days in the past year, underscoring the negative impact of UC on patients' ability to function in the workplace.

"Many patients with ulcerative colitis report experiencing extremely bothersome symptoms, that affect many areas of their lives, including their ability to maintain full-time employment and make and keep social engagements," said Richard J. Geswell, President, Crohn's & Colitis Foundation of America. "Since patients with more severe symptoms experience more difficulties than those with milder disease, a treatment that rapidly reduces UC symptoms and keeps disease activity at bay over time may reduce the impact of the disease on patients' work status and productivity."

About the ACT Long-Term Extension

Patients with moderate to severe UC, defined as a baseline Mayo score greater than or equal to 6 and less than or equal to 12, who were unresponsive to or intolerant to at least one standard therapy, in
'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Anesiva Announces Phase 2 Data Showing Substantial, Long-Term Pain Reductions with Adlea(TM) (formerly 4975) in Osteoarthritis of the Knee
2. Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival
3. Surfaxin (Lucinactant) Long-Term Survival Advantage vs. Comparators Published in Pediatrics
4. New Long-Term Data Analyses for Bifeprunox Show Favorable Effects Versus Placebo in Stabilized Patients with Schizophrenia
5. Medtronic Updates Long-Term ENDEAVOR I-II Clinical Data Showing Sustained Safety and Significant Reductions in Repeat Procedures
6. Taxus VI Clinical Trial Demonstrates Positive Long-Term Outcomes for Moderate-Release Paclitaxel-Eluting Stent at Four Years
7. UCB Presents Long-Term CImzia Data in Crohns Disease
8. PDL BioPharma Announces Long-Term Nuvion Data Presented at 2007 Digestive Disease Week
9. New Study Results Provide Additional Data about Short- and Long-Term Use of Desvenlafaxine Succinate in the Treatment of Adults with Major Depressive Disorder
10. Gilead Announces Presentation of Long-Term Data for Ambrisentan, a Potential Treatment for Patients With Pulmonary Arterial Hypertension
11. CEL-SCI Presents Long-Term Cancer Survival Data With Multikine
Post Your Comments:
(Date:1/6/2009)...E, Md., Jan. 6 Sequella... focused on diseases of epidemic potential, announ...the treatment of tuberculosis (TB), was the first ...inical program contract to Dynport Vaccine Company...arded by the National Institute of Allergy and Inf...
(Date:1/5/2009)...ESDA, Md., Jan. 5 Microm...ompany developing novel, proprietary,antibodies f...mmune diseases,provides an outlook on key events...t intends to provide an update on its research and..., -- April 12 to 16, 2009: Update on several ...
(Date:12/27/2008)...D,S, Bermuda, Dec. 23 Wa...today that one of its subsidiaries and Mayne Pharm...of Hospira, Inc., have filed lawsuits against each..., Mylan Pharmaceuticals Inc. ("Mylan") and Impax L... for the District of New Jersey for infringement o...
(Date:12/17/2008)...est, Most Complex of Its Kind; 80 Percent of Traum..., Dec. 17 A multi-disciplinary tea...ntly performed the first near-total face transpla...procedure performed within the past two weeks, sur...o suffered severe facial trauma -- essentially rep...
Breaking Medicine Technology:Sequella Lead Drug Compound SQ109 Selected for Phase 1B Clinical Trial Program 2Sequella Lead Drug Compound SQ109 Selected for Phase 1B Clinical Trial Program 3Micromet Key Events for 2009 2Micromet Key Events for 2009 3Micromet Key Events for 2009 4Micromet Key Events for 2009 5Warner Chilcott Files Lawsuits for Infringement of DORYX(R) Patent 2Warner Chilcott Files Lawsuits for Infringement of DORYX(R) Patent 3Cleveland Clinic Surgeons Perform Nation's First Near-Total Face Transplant 2Cleveland Clinic Surgeons Perform Nation's First Near-Total Face Transplant 3Six Positive Predictions for 2008 from SuperLife World Service 8518 1Six Positive Predictions for 2008 from SuperLife World Service 8518 2ethiKids inc Launches Website and Products to Address Declining Ethics in Children 8516 1ethiKids inc Launches Website and Products to Address Declining Ethics in Children 8516 2China Sky One Medical Completes Previously Announced Amendments to Form 10QSB for the Second and Third Quarters of 2006 8514 1China Sky One Medical Completes Previously Announced Amendments to Form 10QSB for the Second and Third Quarters of 2006 8514 2AMDLs First Full Service JPGreen Health and Personal Care Center Set to Open in Hangzhou China 2287 1AMDLs First Full Service JPGreen Health and Personal Care Center Set to Open in Hangzhou China 2287 2
...ce suggests that if you,could choose your parents,...ase. Researchers from the long-standing,Framingham...t,Lung, and Blood Institute (NHLBI) of the Nation...parents live longer were more,likely to avoid deve...other risk factors for cardiovascular disease in m...
...3, 2007 -,Cytos Biotechnology AG (SWX:CYTN) report...ith CYT003-QbG10, an immunotherapeutic,product can... study,included 40 patients suffering from mild to...lergy (hay fever). The trial,investigated in a dou...oratory efficacy of two different formulations of ...
Other Medicine Technology:Framingham Study Shows Parents Who Live Long Pass On Lower Risk of,Cardiovascular Disease 2Framingham Study Shows Parents Who Live Long Pass On Lower Risk of,Cardiovascular Disease 3Placebo-controlled Phase IIa Study with the Immunotherapeutic,CYT003-QbG10 Shows Significant Improvement of Allergy Symptoms in,Hay Fever Patients 2Placebo-controlled Phase IIa Study with the Immunotherapeutic,CYT003-QbG10 Shows Significant Improvement of Allergy Symptoms in,Hay Fever Patients 3Placebo-controlled Phase IIa Study with the Immunotherapeutic,CYT003-QbG10 Shows Significant Improvement of Allergy Symptoms in,Hay Fever Patients 4Placebo-controlled Phase IIa Study with the Immunotherapeutic,CYT003-QbG10 Shows Significant Improvement of Allergy Symptoms in,Hay Fever Patients 5Placebo-controlled Phase IIa Study with the Immunotherapeutic,CYT003-QbG10 Shows Significant Improvement of Allergy Symptoms in,Hay Fever Patients 6Placebo-controlled Phase IIa Study with the Immunotherapeutic,CYT003-QbG10 Shows Significant Improvement of Allergy Symptoms in,Hay Fever Patients 7
(Date:1/8/2009)...e introduces Senator Daschle at his confirmation h...n Services , , , WASHINGTON, Jan. 8 /PRNewswi...ounding board member Senator Tom Daschle, nominee ...ary, was introduced by fellow BPC founder and frie...day. The hearing was convened by the Senate Health...
(Date:1/8/2009)...pts Prenatal Solution Key Factor in Decision for F...RLANDO, Fla., Jan. 8 All...LLC, one of the largest multi-specialty group prac... the Allscripts Enterprise(TM) Electronic Health R...cians in 18 offices across Central Florida. , ...
(Date:1/8/2009)...lowered bad cholesterol more effectively than Zoco...-- After nearly a year of review, U.S. health offi...ued use of the controversial cholesterol-lowering ...ration said there was no significant difference in...Vytorin and patients taking the drug Zocor. , B...
(Date:1/8/2009)... local dance students will dance to raise money fo...IS, Jan. 8 , , , WHO: ...show off their talent in the 3rd annual Dance, ...ance Arts Centre. The, event will..., Participants raise money throu...
Breaking Medicine News(10 mins):Health News:Bipartisan Policy Center Founding Board Members Daschle and Dole Appear on Capitol Hill 2Health News:Bipartisan Policy Center Founding Board Members Daschle and Dole Appear on Capitol Hill 3Health News:Bipartisan Policy Center Founding Board Members Daschle and Dole Appear on Capitol Hill 4Health News:Physician Associates, LLC Selects Allscripts Electronic Health Record to Connect and Automate 80 Physicians 2Health News:Physician Associates, LLC Selects Allscripts Electronic Health Record to Connect and Automate 80 Physicians 3Health News:Physician Associates, LLC Selects Allscripts Electronic Health Record to Connect and Automate 80 Physicians 4Health News:FDA Backs Cholesterol Drug Vytorin 2Health News:Dance With Courage to Benefit Camp Courage 2
...a steroid nasal spray to quash allergy symptoms ma...s say that when used on an "as-needed'', rather th...se) relieves// allergy symptoms such as runny nose...vely than the antihistamine loratadine (Claritin)....
...on of intravenous magnesium sulfate to standard em...amide, appears to reduce rather than enhance the e...olleagues from the Albert Einstein College of Medi...vidence that magnesium may be helpful in the treat...
...who smoke during pregnancy are more likely to bear...higher risk than others because of genetic suscept...determine the causes of low birth weight, though t...mmending at this point that women be screened for ...
... of Swiss researchers found that butterbur extract...fects. Mr John de Carpentier said,presumably it co... would not work - and therefore it is possible tha...ons. It was used in treating hayfever The researc...
Other Medicine News:
Aluminum Stylette 16 with Adjustable Stop.
Ultra-Slip™ endotracheal tube guide for single-patient use only., ,Caution: Not MRI Compatible.
Aluminum Stylette 16.
Ultra-Slip™ endotracheal tube guide for single-patient use only., ,Caution: Not MRI Compatible.
Medicine Products: